News

Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the ...
Life sciences firm Danaher raised its annual profit forecast on Tuesday, banking on steady demand for bioprocessing from its pharmaceutical clients and a recovery in China.
Insights from Steven Cohen (Trades, Portfolio)'s First Quarter 2025 13F Filing. Warning! GuruFocus has detected 4 Warning Signs with DHR. Steven Cohen (Trades, Portfolio) recently ...
DHR tops Q2 estimates with strong sales across segments, lifting its 2025 EPS outlook amid mixed margin trends.
The firm's life sciences revenues rose 1 percent, while diagnostics revenues were up 2 percent and biotechnology revenues jumped 8 percent.
The Danaher Business System focuses on continuous improvement, including the acceleration of core growth and margin expansion through marketing initiatives and innovation, which appears positive for ...
Danaher (NYSE:DHR) stock falls even as the company beats Q2 2025 forecasts despite an underperformance at its Life Sciences ...
Danaher (DHR) said that Matthew Gugino, the current group CFO of the company's Life Sciences Innovations Group and VP of Financial Planning & Analysis, will succeed Matthew McGrew ...
" Matt McGrew's financial leadership over the past two decades has been instrumental in shaping the Danaher you see today. He played a pivotal role in the acquisition of Cytiva, the launches of ...
Lockheed Martin was up 0.7%. Wall Street expects it to post second-quarter earnings of $6.52 a share on revenue of $18.57 billion. Medpace Holdings increased 45% after it reported better-than-expected ...
Jennison Associates LLC has taken a bullish stance on Danaher Corporation, snagging 354,555 shares worth approximately $72.68 ...
Danaher Corporation's second quarter results for 2025 show a notable increase in revenue and net earnings, exceeding analyst ...